Happy holidays from Boutique Biotech!

Bio M&A recap for 2023 and trends we're watching for 2024

Bristol Myers Squibb announced the acquisition of Karuna Therapeutics ($KRTX) for $14B to add a first-in-class schizophrenia drug and neuroscience pipeline. Karuna is a name we’ve been following for some time and you can read more about our past coverage of Karuna’s data here.

Karuna’s lead asset is under FDA review with a Sept. 26, 2024 PDUFA date. This…